Pascal Brenneisen: new Chief Executive Officer

TOP 100 Scale-ups

‍

‍

Innosuisse grant awarded

‍

• Transnational project launch with South Korea
• Start-up Innovation Project funding from Innosuisse received

• The European Patent Office granted a patent covering TOP-N53 used for the treatment of chronic wounds.

‍

• Innosuisse grant awarded

‍

• Innosuisse grant awarded

‍

TOP 100 Scale-ups

‍

• Innosuisse grant awarded

‍

• Submission to EMA of Orphan Drug Designation application for TOP-N53

• Completion of TOP-N53 First-in-Man Study

• Positive results from TOP-N53 FIH study

• EMA granted TOP-N53 ODD for the treatment of Digital ulcers in Systemic sclerosis

‍

‍

• Filing of fourth patent

• Dr. Daniel Vasella: new Board Member

‍

• Dosing of First Healthy Subjects in Phase 1 Clinical Study of TOP-N53
• Top100 Swiss Startups

• Filing of third patent

• Innosuisse grant awarded

• Winner of the 6th Dong Sheng Entrepreneurs Cup in Beijing, China
• Top100 Swiss Startups

• Winner of the Young Entrepreneur Award

• Winner Swiss Innovation Challenge

• Successful Series B Financial Round
• Top100 Swiss Startups 2018

• Innosuisse grant awarded

• Winner of the prestigious Swiss Economic Award

• CTI grant awarded

• Filing of second patent

• Top100 Swiss Startups

• EUROSTARS grant awarded

• CTI grant awarded

• Successful Series A Financial Round

• CTI Certification

• Winner Venture Leaders Life Science

• Top 100 Swiss Startups

• Winner IMD Startup

• Foundation Topadur Pharma AG

• Technical Closing Seed funding

• Co-Winner Pitching Battle CEO day

• Coaching Acceptance granted by CTI Committee

• Filing of first patent for TOP-N53

• Headquarters / Labs established in Schlieren, Switzerland
• Finalist Swiss Innovation Challenge

Experimental research phase

• Foundation TOPADUR GmbH